| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,306,425 ) |
| | 2025 | 2025 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA278187 | A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | 000 | 3 | NIH | 6/6/2025 | $679,155 |
| | 2025 | 2025 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA291622 | A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | 002 | 2 | NIH | 4/24/2025 | $627,270 |
| | 2025 | 2024 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA291622 | A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | 000 | 1 | NIH | 10/9/2024 | $0 |
| | 2025 | 2024 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA291622 | A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | 001 | 1 | NIH | 4/23/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,145,050 ) |
| | 2024 | 2024 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA278187 | A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | 000 | 2 | NIH | 6/12/2024 | $745,050 |
| | 2024 | 2024 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA291622 | A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | 000 | 1 | NIH | 9/16/2024 | $400,000 |
| | 2024 | 2021 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 4 | NIH | 3/1/2024 | $0 |
| | 2024 | 2020 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 000 | 3 | NIH | 2/28/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $400,000 ) |
| | 2023 | 2023 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44CA278187 | A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | 001 | 1 | NIH | 8/21/2023 | $0 |
| | 2023 | 2023 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA278187 | A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | 000 | 1 | NIH | 7/7/2023 | $400,000 |
| | 2023 | 2020 | SYNTRIX BIOSYSTEMS INC. | 215 CLAY ST NW | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 000 | 2 | NIH | 6/23/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = -$6,220 ) |
| | 2022 | 2021 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 4 | NIH | 1/28/2022 | $0 |
| | 2022 | 2021 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 001 | 2 | NIH | 1/28/2022 | $0 |
| | 2022 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 000 | 3 | NIH | 1/28/2022 | $0 |
| | 2022 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 001 | 3 | NIH | 7/28/2022 | $0 |
| | 2022 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 000 | 2 | NIH | 1/28/2022 | $0 |
| | 2022 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | U44AI114473 | Efficacy and resistance mechanisms of LD-aminopterin in psoriasis | 000 | 4 | NIH | 3/24/2022 | -$6,220 |
|
| Issue Date FY: 2021 ( Subtotal = $731,545 ) |
| | 2021 | 2021 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 001 | 4 | NIH | 8/10/2021 | $651,354 |
| | 2021 | 2021 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 002 | 2 | NIH | 5/27/2021 | $80,191 |
| | 2021 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 3 | NIH | 8/9/2021 | $0 |
| | 2021 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 001 | 2 | NIH | 2/18/2021 | $30,727 |
| | 2021 | 2019 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 000 | 1 | NIH | 2/18/2021 | -$30,727 |
| | 2021 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA027304 | Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine | 000 | 7 | NIH | 3/24/2021 | $0 |
| | 2021 | 2017 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA040378 | Phase II clinical evaluation of Omnitram in neuropathic pain | 000 | 3 | NIH | 3/24/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,003,559 ) |
| | 2020 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 3 | NIH | 6/11/2020 | $223,334 |
| | 2020 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 001 | 3 | NIH | 9/4/2020 | $1,575,472 |
| | 2020 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 003 | 2 | NIH | 8/14/2020 | $5,484 |
| | 2020 | 2020 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 002 | 2 | NIH | 3/31/2020 | $1,199,269 |
| | 2020 | 2019 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 000 | 1 | NIH | 11/26/2019 | $0 |
| | 2020 | 2019 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 001 | 1 | NIH | 3/31/2020 | $0 |
| | 2020 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | U44AI114473 | Efficacy and resistance mechanisms of LD-aminopterin in psoriasis | 000 | 4 | NIH | 3/26/2020 | $0 |
| | 2020 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 000 | 1 | NIH | 5/16/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,628,915 ) |
| | 2019 | 2019 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 000 | 2 | NIH | 8/12/2019 | $1,424,426 |
| | 2019 | 2019 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA046316 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | 000 | 1 | NIH | 5/7/2019 | $204,489 |
| | 2019 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 001 | 2 | NIH | 8/19/2019 | $0 |
| | 2019 | 2017 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 1 | NIH | 7/30/2019 | $0 |
| | 2019 | 2017 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA040378 | Phase II clinical evaluation of Omnitram in neuropathic pain | 000 | 3 | NIH | 7/30/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,804,836 ) |
| | 2018 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | U44AI114473 | Efficacy and resistance mechanisms of LD-aminopterin in psoriasis | 000 | 4 | NIH | 2/3/2018 | $304,057 |
| | 2018 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44HL142389 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | 000 | 1 | NIH | 8/24/2018 | $398,444 |
| | 2018 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 001 | 2 | NIH | 8/3/2018 | $1,125,311 |
| | 2018 | 2018 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44DA027304 | Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine | 000 | 7 | NIH | 8/14/2018 | $977,024 |
| | 2018 | 2017 | SYNTRIX BIOSYSTEMS, INC. | 215 CLAY ST NW STE B-5 | AUBURN | WA | 98001-4213 | KING | USA | R44CA217591 | A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | 000 | 1 | NIH | 8/3/2018 | $0 |
|
|
